Unknown

Dataset Information

0

Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas.


ABSTRACT: High-grade gliomas defined by histone 3 K27M driver mutations exhibit global loss of H3K27 trimethylation and reciprocal gain of H3K27 acetylation, respectively shaping repressive and active chromatin landscapes. We generated tumor-derived isogenic models bearing this mutation and show that it leads to pervasive H3K27ac deposition across the genome. In turn, active enhancers and promoters are not created de novo and instead reflect the epigenomic landscape of the cell of origin. H3K27ac is enriched at repeat elements, resulting in their increased expression, which in turn can be further amplified by DNA demethylation and histone deacetylase inhibitors providing an exquisite therapeutic vulnerability. These agents may therefore modulate anti-tumor immune responses as a therapeutic modality for this untreatable disease.

SUBMITTER: Krug B 

PROVIDER: S-EPMC6521975 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications


High-grade gliomas defined by histone 3 K27M driver mutations exhibit global loss of H3K27 trimethylation and reciprocal gain of H3K27 acetylation, respectively shaping repressive and active chromatin landscapes. We generated tumor-derived isogenic models bearing this mutation and show that it leads to pervasive H3K27ac deposition across the genome. In turn, active enhancers and promoters are not created de novo and instead reflect the epigenomic landscape of the cell of origin. H3K27ac is enric  ...[more]

Similar Datasets

2019-05-13 | GSE128745 | GEO
2019-05-13 | GSE117446 | GEO
2019-05-13 | GSE129135 | GEO
2019-05-13 | GSE128744 | GEO
2019-05-13 | GSE129136 | GEO
| PRJNA528663 | ENA
| EGAS00001003572 | EGA
| PRJNA482128 | ENA
| PRJNA528664 | ENA
| PRJNA530223 | ENA